For questions about BMS medicines during this time please call 1-800-721-8909.

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Close

This site is intended for U.S. healthcare professionals.

About ONUREG®

24.7 MONTHS MEDIAN OS1

ONUREG® demonstrated >2 years median overall survival for AML patients in first remission

24.7 months (95% CI: 18.7, 30.5) median OS with ONUREG® vs 14.8 months (95% CI: 11.7, 17.6) with placebo (HR 0.69 [95% CI: 0.55, 0.86; P=0.0009])

ONUREG® SAFETY ASSESSED IN THE QUAZAR® AML-001 TRIAL1

Warnings and Precautions: Risks of Substitution with Other Azacitidine Products; Myelosuppression; Increased Early Mortality in Patients with Myelodysplastic Syndromes; Embryo-Fetal Toxicity

The most common adverse reactions (ARs) (≥10%) are nausea, vomiting, diarrhea, fatigue/asthenia, constipation, pneumonia, abdominal pain, arthralgia, decreased appetite, febrile neutropenia, dizziness, and pain in extremity

2 weeks on | 2 weeks off
CONVENIENT ORAL DOSING1,2

Patients can take ONUREG® at home

One 300 mg tablet orally, once daily with or without food on Days 1-14 of each 28-day treatment cycle

It is recommended that patients take an antiemetic 30 minutes prior to each dose of ONUREG® for the first 2 cycles

Continue ONUREG® until disease progression or unacceptable toxicity

Continue the conversation

Enter your email address and we'll have a BMS representative get in touch to discuss how ONUREG® may help your appropriate patients with AML who are in first remission.

*Required field

Bristol-Myers Squibb Company values your privacy. Bristol-Myers Squibb Company, its affiliates, and its agents will not sell or rent your personal information. By providing your information, you acknowledge that you have read and agree to the Bristol-Myers Squibb Company Privacy Policy.